Pharmacodynamics and long-term toxicity of etoposide
Authors:
- 1 January 1994
- journal article
- review article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 34 (S1) , S64-S68
Abstract
Etoposide has been used in the treatment of a wide variety of neoplasms, including small-cell lung cancer, Kaposi's sarcoma, testicular cancer, acute leukemia, and lymphoma. Its current therapeutic use is limited by myelosuppression, particularly neutropenia. Pharmacodynamic studies of etoposide show that this toxicity can be modeled using a modified Hill equation and that the dose intensity of etoposide can be successfully increased by adaptive control using this model. Significant influences on the degree of myelosuppression include the pretreatment leukocyte count, the performance status, the extent of prior erythrocyte transfusions, and the serum albumin level. In the past 7 years, interest has developed in a distinct subset of acute nonlymphocytic leukemia that is associated with prior exposure to etoposide. This syndrome has been described in several studies and is characterized by the lack of a preleukemic phase, M4 or M5 morphology, and distinct translocations involving the chromosome 11q23 region. In addition, secondary acute lymphocytic leukemias (involving 11q23) have also been associated with prior epipodophyllotoxin exposure.Keywords
This publication has 53 references indexed in Scilit:
- Acute Myeloid Leukemia After Single-Agent Treatment with Etoposide for Langerhansʼ Cell Histiocytosis of BoneJournal of Pediatric Hematology/Oncology, 1993
- High Frequency of Etoposide (VP-16)-Related Secondary Leukemia in Children with Non-Hodgkinʼs LymphomaJournal of Pediatric Hematology/Oncology, 1993
- Secondary Leukemia Associated With a Conventional Dose of Etoposide: Review of Serial Germ Cell Tumor ProtocolsJNCI: Journal of the National Cancer Institute, 1993
- Secondary leukaemias after epipodophyllotoxinsThe Lancet, 1992
- Increased frequency of chromosomal damage in peripheral blood lymphocytes up to nine years following curative chemotherapy of patients with testicular carcinomaEnvironmental and Molecular Mutagenesis, 1991
- Chromosome aberrations induced by etoposide (VP‐16) are not randomInternational Journal of Cancer, 1990
- Myeloid neoplasia in children treated for solid tumoursThe Lancet, 1990
- Serial Measurement of Sister Chromatid Exchanges in the Peripheral Lymphocytes of Patients with Lung Cancer Receiving Chemotherapy in Relation to Bone Marrow ToxicityJapanese Journal of Cancer Research, 1989
- Secondary Acute Myeloid Leukemia in Children Treated for Acute Lymphoid LeukemiaNew England Journal of Medicine, 1989
- Correlations between sister chromatid exchange frequencies and replicon sizesExperimental Cell Research, 1981